Print Page  Close Window

Investor Relations
Corporate Profile
Zogenix, Inc. (Nasdaq: ZGNX) is a pharmaceutical company committed to developing and commercializing therapies that address specific clinical needs for people living with CNS disorders who need innovative treatment alternatives to help them return to normal daily functioning. ... More >>
Latest PresentationsMore >>
Title
Download Documentation Zogenix September 2015 Investor Presentation
Get help downloading or viewing the above file types
Stock Quote
ZGNX (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$19.76
Change (%) Stock is Up 0.13 (0.66%)
Volume461,394
Data as of 09/04/15 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
DateTitle 
09/03/15Zogenix to Participate in the Wells Fargo 2015 Healthcare Conference
SAN DIEGO, Sept. 3, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced that Stephen J. Farr, Ph.D., President and CEO, will present a corporate update at the Wells Fargo 2015 Healthcare Conference in Boston, MA, on September 10, 2015. Wells Fargo 2015 Healthcare Conference Date: Thursday, September 10, 2015 T... 
Printer Friendly Version
08/10/15Zogenix Provides Corporate Update and Reports Second Quarter 2015 Financial Results
Company Will Host a Conference Call Today at 4:30 p.m. EDT/1:30 p.m. PDT SAN DIEGO, Aug. 10, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, provided a corporate update, and announced financial results for the second quarter ended June 30, 2015. Corporate Update Presented new data at European Paediatric Neurology Society Congress in Vienna, Austria, de... 
Printer Friendly Version
08/05/15Zogenix Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
SAN DIEGO, Aug. 5, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing unique therapies for the treatment of central nervous system (CNS) disorders, announced today the closing of its previously announced underwritten public offering of 5,462,500 shares of its common stock, including 712,500 shares sold pursuant to the underwriters' full exercise of their option to purchase additional shares, at a price to the public of $18.00 per share. ... 
Printer Friendly Version
08/03/15Zogenix to Release Second Quarter 2015 Financial Results and Host Conference Call & Webcast on August 10
SAN DIEGO, Aug. 3, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, today announced that it will report its financial results for the second quarter ended June 30, 2015 after the market close, and will host a corporate update conference call and webcast on Monday, August 10, 2015 at 4:30pm Eastern Time. Monday, August 10, 2015 @ 4:30pm Eastern Time/... 
Printer Friendly Version
Upcoming EventsMore >>
DateTitle
09/10/15 8:35 a.m. ET
Zogenix, Inc. at Wells Fargo 2015 Healthcare Conference
LocationBoston, MA

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.